Cellectar Biosciences Files 8-K on Financials
Ticker: CLRB · Form: 8-K · Filed: May 14, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | May 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cellectar filed an 8-K for financial updates, check for details.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing provides an update on Cellectar Biosciences' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
- 100 Campus Drive, Florham Park, NJ 07932 (address) — Principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not detail the specific financial figures within this excerpt.
What is the primary purpose of this 8-K filing for Cellectar Biosciences?
The primary purpose is to report on the company's results of operations and financial condition, along with associated financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 14, 2024.
What is Cellectar Biosciences' principal executive office address?
Cellectar Biosciences' principal executive offices are located at 100 Campus Drive, Florham Park, NJ 07932.
Does this filing mention any significant changes in the company's business or operations?
The filing is categorized under 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' suggesting a focus on financial performance rather than explicitly detailing operational changes in the provided text.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-14 06:45:17
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm2414381d1_8k.htm (8-K) — 25KB
- tm2414381d1_ex99-1.htm (EX-99.1) — 62KB
- 0001104659-24-060865.txt ( ) — 264KB
- clrb-20240514.xsd (EX-101.SCH) — 3KB
- clrb-20240514_lab.xml (EX-101.LAB) — 33KB
- clrb-20240514_pre.xml (EX-101.PRE) — 22KB
- tm2414381d1_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. On May 14, 2024, we issued a press release announcing our financial results for the quarter ended March 31, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated May 14, 2024, titled "Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: May 14, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer